HIIT helps combat high insulin resistance -- a warning sign for diabetes

This variability in response to exercise is well known, but has usually been investigated in people undergoing traditional endurance exercise programmes. High-Intensity Interval Training (HIIT), a more recent alternative to these exercise programmes, is more time-efficient and has been shown to improve different health-related metrics in other cohorts.

Professor Izquierdo and his team therefore set out to see if a HIIT programme could help more people cut the levels of insulin and glucose in their blood and lower their risk of developing type-2 diabetes, regardless of their level of insulin resistance. Other measures such as weight, blood pressure and waist circumference, which are associated with other cardiometabolic diseases like high blood pressure, were also monitored. The team's goal was to find an efficient way of reducing people's risk of developing cardiometabolic diseases in the future, and to work out which people will benefit from which exercise programmes most.

Forty sedentary adult women at risk for type-2 diabetes mellitus -- a similar sample size to comparable exercise training studies -- underwent a ten-week programme of HIIT, alongside close monitoring of their cardiometabolic health. The women were divided into two groups based on their level of insulin resistance, and the differences between their responses to the exercise programme were compared. Generally, the HIIT programme brought about positive changes in cardiometabolic health metrics. More women in the higher-risk group saw benefits from the exercise programme, particularly when it came to their blood pressure and the levels of glucose and insulin found in their blood. Women in both groups lost weight and body fat after the exercise programme.

Based on this, the authors suggest that High-Intensity Interval Training is a promising exercise programme that offers many people a chance to improve their cardiometabolic health. The study also takes a step towards improving our understanding of non-responders in exercise programmes, and working out which interventions will help which people. However, Professor Izquierdo cautioned that different researchers have described non-responders in different ways, which makes it very difficult to compare rates of non-response across studies and determine the best clinical practice. He added that, in the future, the influence of genetics and of other cardiometabolic diseases -- such as hypertension -- should be taken into account.

However, whatever the improvements needed for the future, Professor Izquierdo and his team welcome this step towards giving more people more effective ways to stop type-2 diabetes before it strikes.